Worth reading
35Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.This transaction
This business transferCounterparty日本予防医薬株式会社（譲受会社）
Disclosing companySoiken Holdings Inc.
TimelineThe spacing between the points is proportional to the actual number of days.11 days from 決議 / 締結 to 実行.White points represent dates designated as scheduled dates in the document.
Target company
Research and development, manufacture and sale, and export of cosmetics
Location Shibuya, TokyoShare capital ¥53 millionDate of incorporation 7 November 1997
Consideration and expenses
Acquisition price本事業譲渡の効力発生日における譲渡資産の帳簿価額を基礎とする予定です
Impact on Business Performance
当社連結業績に与える影響は軽微であります
Procedures and assumptions
Valuation methodology譲渡資産の帳簿価額を基礎とする予定
Conditions Precedent to Execution株式会社ビービーラボラトリーズの事業譲渡契約承認株主総会の承認
Management structure after acquisition日本予防医薬がプラセンタ製品を中心とした化粧品ブランドを立ち上げ、EC販売ノウハウ、販路、顧客基盤を融合して事業を継続する。商号、代表者、従業員の処遇についてはNot disclosed
| Item | Details |
|---|---|
| Transaction name | This business transfer |
| Counterparty name | 日本予防医薬株式会社（譲受会社） |
| Name of the Subject Company | 株式会社ビービーラボラトリーズ（譲渡会社） |
| Business Description of the Subject Company | Research and development, manufacture and sale, and export of cosmetics |
| Location of the Subject Company | Shibuya, Tokyo |
| Capital Stock of the Subject Company | ¥53 million |
| Date of Establishment of the Subject Company | 7 November 1997 |
| Acquisition price | 本事業譲渡の効力発生日における譲渡資産の帳簿価額を基礎とする予定です |
| Impact on Business Performance | 当社連結業績に与える影響は軽微であります |
| Date of board resolution | 2026年2月18日（当社および日本予防医薬） |
| Contract Date | 18 February 2026 |
| Execution Date / Effective Date | 2026年3月1日（予定） |
| Valuation methodology | 譲渡資産の帳簿価額を基礎とする予定 |
| Conditions Precedent to Execution | 株式会社ビービーラボラトリーズの事業譲渡契約承認株主総会の承認 |
| Management structure after acquisition | 日本予防医薬がプラセンタ製品を中心とした化粧品ブランドを立ち上げ、EC販売ノウハウ、販路、顧客基盤を融合して事業を継続する。商号、代表者、従業員の処遇についてはNot disclosed |
Items this document does not state (17)
Net Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredVoting rights ownership percentageFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Independent valuation institutionSpecial Committee
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.事業ポートフォリオの最適化を含む構造改革の一環です。Bblは中国市場への依存度が高く大幅な業績回復が見込みづらいため事業活動を終了する一方、日本国内基盤の主力製品であるプラセンタ製品の化粧品事業は、日本予防医薬のEC販売ノウハウ、販路、顧客基盤を活用して継続するとしています。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.